{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:56:30Z","timestamp":1771469790876,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.leukres.2007.07.017","type":"journal-article","created":{"date-parts":[[2007,9,11]],"date-time":"2007-09-11T11:08:46Z","timestamp":1189508926000},"page":"465-473","source":"Crossref","is-referenced-by-count":27,"title":["Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux"],"prefix":"10.1016","volume":"32","author":[{"given":"MyDoanh","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred M.","family":"Ajami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Capizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2007.07.017_bib1","series-title":"Cancer Medicine","first-page":"1739","article-title":"Acute myeloid leukemia in adults mast cell leukemia and other mast cell neoplasms","author":"Schiffer","year":"2006"},{"key":"10.1016\/j.leukres.2007.07.017_bib2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukaemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2007.07.017_bib3","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib4","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2006-08-041152","article-title":"End points to establish the efficacy of new agents in the treatment of acute leukemia","volume":"109","author":"Appelbaum","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232","article-title":"Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720","volume":"100","author":"Baer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib6","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.bi.62.070193.002125","article-title":"Biochemistry of multidrug resistance mediated by the multidrug transporter","volume":"62","author":"Gottesman","year":"1993","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.leukres.2007.07.017_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/PL00000912","article-title":"From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance","volume":"58","author":"Litman","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.leukres.2007.07.017_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szakacs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.leukres.2007.07.017_bib10","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V86.6.2329.bloodjournal8662329","article-title":"Correlation of multidrug resistance (MDR1) protein expression with functional dye\/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR\u2212\/efflux+ and MDR1+\/efflux\u2212 cases","volume":"86","author":"Leith","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib11","first-page":"910","article-title":"Clinical significance of multidrug resistance in AML: current insights","volume":"3","author":"Baer","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.leukres.2007.07.017_bib12","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","article-title":"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)","volume":"22","author":"Greenberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.07.017_bib13","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2001.19.6.1589","article-title":"Phase I\/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia","volume":"19","author":"Dorr","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.07.017_bib14","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2004.11.106","volume":"22","author":"Kolitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.07.017_bib15","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1182\/blood-2005-04-1395","article-title":"The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis","volume":"106","author":"van der Holt","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib16","doi-asserted-by":"crossref","first-page":"129a","DOI":"10.1182\/blood.V108.11.423.423","volume":"108","author":"Cripe","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.beha.2006.11.006","article-title":"Targeted agents in AML: much more to do","volume":"20","author":"Stone","year":"2007","journal-title":"Best Prac Res Clin Haematol"},{"key":"10.1016\/j.leukres.2007.07.017_bib18","first-page":"371","article-title":"Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs","volume":"36","author":"Hsiang","year":"1989","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.leukres.2007.07.017_bib19","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1021\/jm960623g","article-title":"2-[2\u2032-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10 and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships","volume":"39","author":"Sami","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2007.07.017_bib20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1021\/jm950742g","article-title":"Six- and 7-substituted 2-[2\u2032-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure\u2013activity relationships","volume":"39","author":"Sami","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2007.07.017_bib21","first-page":"935","article-title":"Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia","volume":"51","author":"O\u2019Brien","year":"1991","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2007.07.017_bib22","first-page":"31a","article-title":"Phase 1 trial of amonafide for poor prognosis acute leukemias and blast crisis of chronic myelogenous leukemia","volume":"78","author":"Allen","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib23","first-page":"276","article-title":"Phase 1 trial of amonafide for refractory, relapsed, or secondary acute leukemias and blast crisis chronic myelogenous leukemia","volume":"11","author":"Allen","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2007.07.017_bib24","first-page":"32","article-title":"Phase 1 trial of amonafide (AM) for poor prognosis acute leukemias","volume":"15","author":"Allen","year":"1991","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.07.017_bib25","first-page":"225","article-title":"Phase 1 trial of amonafide and cytosine arabinoside for poor risk acute leukemias","volume":"35","author":"Allen","year":"1994","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.leukres.2007.07.017_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0022-3565(24)29270-3","article-title":"Rational use of in vitro P-glycoprotein assays in drug discovery","volume":"299","author":"Polli","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2007.07.017_bib27","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/1078-0432.CCR-04-1725","article-title":"Cyclosporin A is a broad-spectrum multidrug resistance modulator","volume":"11","author":"Qadir","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2007.07.017_bib28","first-page":"167","article-title":"Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro","volume":"87","author":"Ganeshaguru","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2007.07.017_bib29","first-page":"1086","article-title":"Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1\/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study","volume":"94","author":"Leith","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.07.017_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/25.7.894009","article-title":"Proof without prejudice: use of the Kolmogorov\u2013Smirnov test for the analysis of histograms from flow systems and other sources","volume":"25","author":"Young","year":"1977","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.leukres.2007.07.017_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.leukres.2007.07.017_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0014-4827(91)90452-Z","article-title":"Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative","volume":"196","author":"Boesch","year":"1991","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2007.07.017_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cyto.990200305","article-title":"Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance","volume":"20","author":"Frey","year":"1995","journal-title":"Cytometry"},{"key":"10.1016\/j.leukres.2007.07.017_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF00684879","article-title":"P-glycoprotein expression and modulation of cell-membrane morphology in adriamycin-resistant P388 leukemia cells","volume":"25","author":"Radel","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2007.07.017_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/mp050095h","article-title":"Scientific perspectives on drug transporters and their role in drug interactions","volume":"3","author":"Zhang","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1016\/j.leukres.2007.07.017_bib36","series-title":"Pharmaceutical Profiling in Drug Discovery for Lead Selection","article-title":"Cultured epithelial cell assays used to estimate intestinal absorption potential","author":"Weinstein","year":"2004"},{"key":"10.1016\/j.leukres.2007.07.017_bib37","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.leukres.2006.03.014","article-title":"Will MDR-1\/P-gp modulators provide clinical benefit in hematologic malignancies?","volume":"30","author":"Mahadevan","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.07.017_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1568011013354624","article-title":"Naphthalimides as anti-cancer agents: synthesis and biological activity","volume":"1","author":"Brana","year":"2001","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"10.1016\/j.leukres.2007.07.017_bib39","doi-asserted-by":"crossref","first-page":"15990","DOI":"10.1074\/jbc.M011143200","article-title":"ATP-bound topoisomerase II as a target for antitumor drugs","volume":"276","author":"Wang","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2007.07.017_bib40","first-page":"585s","article-title":"Phase I study of amonafide+cytosine arbinoside (AraC) in patients with poor risk acute myeloid leukemia (AML)","volume":"23","author":"Allen","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2007.07.017_bib41","first-page":"373s","article-title":"Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)","volume":"25","author":"Erba","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.leukres.2007.07.017_bib42","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","article-title":"A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study (9031)","volume":"91","author":"Godwin","year":"1998","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607003025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607003025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T23:15:45Z","timestamp":1737414945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212607003025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0145212607003025"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2007.07.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}